MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
MEDIPOST’s CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial Demonstrates Statistically Significant Efficacy Gains Versus Active Control
MEDIPOST Announces the Exclusive Commercialization License Agreement with Teikoku Seiyaku for Knee Osteoarthritis Treatment CARTISTEM® in Japan
MEDIPOST Completes Administration for Phase 3 Clinical Trial of CARTISTEM® for Knee Osteoarthritis in Japan
MEDIPOST Discusses CARTISTEM® Partnerships and Licensing Opportunities at Global Bio-Pharma Events in US and Japan
MEDIPOST Submits Application for Product Authorization Amendment to Add Ankle Indications for CARTISTEM®
MEDIPOST’s CARTISEM®, Umbilical Cord Blood-derived Stem Cell Transplant Surgery Clinical Study Results Published in SCI-Level Journal
MEDIPOST Treats First Subject with CARTISTEM® in Japan Phase 3 Clinical Trial, Accelerating Clinical Development efforts in Japan
